KR20240022560A - 바이러스 감염의 신경학적 합병증의 치료 및 예방을 위한 신규 화합물 - Google Patents
바이러스 감염의 신경학적 합병증의 치료 및 예방을 위한 신규 화합물 Download PDFInfo
- Publication number
- KR20240022560A KR20240022560A KR1020247001041A KR20247001041A KR20240022560A KR 20240022560 A KR20240022560 A KR 20240022560A KR 1020247001041 A KR1020247001041 A KR 1020247001041A KR 20247001041 A KR20247001041 A KR 20247001041A KR 20240022560 A KR20240022560 A KR 20240022560A
- Authority
- KR
- South Korea
- Prior art keywords
- compound
- ophioglossum
- metabolite
- pharmaceutical composition
- day
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/02—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
- C07C69/22—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety
- C07C69/30—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety esterified with trihydroxylic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/11—Pteridophyta or Filicophyta (ferns)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/11—Pteridophyta or Filicophyta (ferns)
- A61K36/12—Filicopsida or Pteridopsida
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Emergency Medicine (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21180462.0 | 2021-06-18 | ||
| EP21180462 | 2021-06-18 | ||
| PCT/EP2022/066548 WO2022263624A1 (en) | 2021-06-18 | 2022-06-17 | Novel compounds for the treatment and prevention of neurological complications of viral infections |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20240022560A true KR20240022560A (ko) | 2024-02-20 |
Family
ID=76532115
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020247001041A Pending KR20240022560A (ko) | 2021-06-18 | 2022-06-17 | 바이러스 감염의 신경학적 합병증의 치료 및 예방을 위한 신규 화합물 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20240307339A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4355316A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024523429A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240022560A (cg-RX-API-DMAC7.html) |
| CN (1) | CN117529311A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022263624A1 (cg-RX-API-DMAC7.html) |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4150125A (en) * | 1977-09-30 | 1979-04-17 | Abbott Laboratories | Triglyceride ester of phosphonoacetic acid having antiviral activity |
| JP2000007581A (ja) * | 1998-06-18 | 2000-01-11 | Nippon Kayaku Co Ltd | 抗ウイルススプレー剤 |
| KR20120129898A (ko) * | 2009-12-30 | 2012-11-28 | 베일러 리서치 인스티튜트 | 알츠하이머 질환 및 노화 뇌를 위한 보충대사 치료요법 |
| CN104940589A (zh) * | 2015-06-18 | 2015-09-30 | 王峰 | 治疗急性结膜炎的中药制剂及制法 |
| NZ749389A (en) * | 2016-06-08 | 2022-12-23 | Sunregen Healthcare Ag | Lipids with odd number of carbon atoms and their use as pharmaceutical composition or nutritional supplement |
| WO2018159941A1 (ko) * | 2017-03-02 | 2018-09-07 | 대화제약 주식회사 | 자나미비르를 포함하는 안정한 약제학적 조성물 |
| KR101991661B1 (ko) * | 2017-03-02 | 2019-06-21 | 대화제약 주식회사 | 자나미비르를 포함하는 안정한 약제학적 조성물 |
| WO2019052629A1 (en) * | 2017-09-12 | 2019-03-21 | Sunregen Healthcare Ag | LIPIDS HAVING AN IMPERATIVE NUMBER OF CARBON ATOMS AND THEIR USE AS A PHARMACEUTICAL COMPOSITION OR FOOD SUPPLEMENT |
-
2022
- 2022-06-17 JP JP2023578116A patent/JP2024523429A/ja active Pending
- 2022-06-17 KR KR1020247001041A patent/KR20240022560A/ko active Pending
- 2022-06-17 EP EP22734578.2A patent/EP4355316A1/en active Pending
- 2022-06-17 US US18/571,123 patent/US20240307339A1/en active Pending
- 2022-06-17 WO PCT/EP2022/066548 patent/WO2022263624A1/en not_active Ceased
- 2022-06-17 CN CN202280043349.6A patent/CN117529311A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022263624A1 (en) | 2022-12-22 |
| US20240307339A1 (en) | 2024-09-19 |
| CN117529311A (zh) | 2024-02-06 |
| JP2024523429A (ja) | 2024-06-28 |
| EP4355316A1 (en) | 2024-04-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wang et al. | Simvastatin prevents β-amyloid25–35-impaired neurogenesis in hippocampal dentate gyrus through α7nAChR-dependent cascading PI3K-Akt and increasing BDNF via reduction of farnesyl pyrophosphate | |
| Uthayathas | Versatile effects of sildenafil: recent pharmacological applications | |
| Tsubura et al. | Animal models for retinitis pigmentosa induced by MNU; disease progression, mechanisms and therapeutic trials | |
| Sun et al. | Dexmedetomidine exerts a protective effect on ischemic brain injury by inhibiting the P2X7R/NLRP3/Caspase-1 signaling pathway | |
| CN110300581B (zh) | 具有奇数碳的脂类化合物及其作为医药组合物或者营养补充剂的用途 | |
| Kang et al. | Roots of Lithospermum erythrorhizon promotes retinal cell survival in optic nerve crush-induced retinal degeneration | |
| US20230078820A1 (en) | Fenfluramine for treatment of demyelinating diseases and conditions | |
| WO2018113027A1 (zh) | 白果内酯作为增效剂在制备防治脑神经损伤性疾病药物的应用 | |
| Wareham et al. | Increased bioavailability of cyclic guanylate monophosphate prevents retinal ganglion cell degeneration | |
| US20210317455A1 (en) | Inhibitor of tdp-43 aggregation | |
| JP5783377B2 (ja) | 網膜色素変性症を予防する及び遅発させるためのセリンパルミトイルトランスフェラーゼ阻害剤 | |
| Salama et al. | Naringin attenuates D-galactose-induced brain aging via regulation of oxidative stress markers TNF-α, NF-κβ and modulation of the neurotrophic markers PGC1-α, NT-3 AGEs, and GFAP in vivo | |
| KR20160012184A (ko) | 뉴런 세포에서의 단백질 응집체 침착을 특징으로 하는 질환을 치료하는데 사용하기 위한 타크롤리무스 | |
| Lee et al. | The effects of Korean Red Ginseng-derived components on oligodendrocyte lineage cells: Distinct facilitatory roles of the non-saponin and saponin fractions, and Rb1, in proliferation, differentiation and myelination | |
| US20240307339A1 (en) | Novel compounds for the treatment and prevention of neurological complications of viral infections | |
| US20160354392A1 (en) | Mitochondria-targeted antioxidants for treatment of age-related brain disorders | |
| Belayev et al. | LAU-0901, a novel platelet-activating factor receptor antagonist, confers enduring neuroprotection in experimental focal cerebral ischemia in the rat | |
| JP2020007376A (ja) | リポカリン型プロスタグランジンd2合成酵素産生促進剤 | |
| Efimenko et al. | Studies to elucidate the effect and antiapop-totic mechanism of 2-ethyl-3-hydroxy-6-methylpyridine-n-acetyltaurinate in a rat model of retinal ischemia–reperfusion | |
| CN106074585A (zh) | 人参皂苷Rb1和Rd组合及其在制备治疗光感受器细胞死亡相关疾病的药物中的应用 | |
| TWI587860B (zh) | 喹啉衍生化合物用於製備Tau蛋白病變類疾病之醫藥組成物上之用途 | |
| HK40021759B (en) | Lipids with odd number of carbon atoms and their use as pharmaceutical composition or nutritional supplement | |
| US20230398088A1 (en) | Lipid Prophylactic Brain Injury Treatment | |
| TWI650121B (zh) | 化合物用於製備Tau蛋白病變類疾病之醫藥組成物上之用途 | |
| Li et al. | Stimulation of Thyroid Hormone Signaling Induces Stress |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| A201 | Request for examination | ||
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |